Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Receivables (2017 - 2025)

Heron Therapeutics' Change in Receivables history spans 11 years, with the latest figure at $8.5 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 27.88% year-over-year to $8.5 million; the TTM value through Dec 2025 reached $10.7 million, down 42.88%, while the annual FY2025 figure was $10.7 million, 42.88% down from the prior year.
  • Change in Receivables reached $8.5 million in Q4 2025 per HRTX's latest filing, up from $1.1 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $25.2 million in Q2 2023 to a low of -$12.9 million in Q3 2023.
  • Average Change in Receivables over 5 years is $2.4 million, with a median of $1.2 million recorded in 2025.
  • The largest YoY upside for Change in Receivables was 3255.62% in 2023 against a maximum downside of 784.24% in 2023.
  • A 5-year view of Change in Receivables shows it stood at -$7.6 million in 2021, then skyrocketed by 229.97% to $9.9 million in 2022, then crashed by 137.1% to -$3.7 million in 2023, then soared by 423.73% to $11.8 million in 2024, then fell by 27.88% to $8.5 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Change in Receivables are $8.5 million (Q4 2025), $1.1 million (Q3 2025), and $1.2 million (Q2 2025).